These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 9360162)

  • 21. Automated protamine dose assay in heparin reversal management after cardiopulmonary by pass.
    Guarracino F; De Cosmo D; Penzo D; Tedesco M; Bossi A; Zussa C; Polesel E; De Stefani R
    Minerva Anestesiol; 2001 Apr; 67(4):165-9. PubMed ID: 11376504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist.
    Cushing DJ; Cooper WD; Cohen ML; McVoy JR; Sobel M; Harris RB
    Eur J Pharmacol; 2010 Jun; 635(1-3):165-70. PubMed ID: 20307530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery.
    Taneja R; Marwaha G; Sinha P; Quantz M; Stitt L; Gao R; Subramanian S; Schaus M; Keeney M; Chin-Yee I; Murkin J
    Can J Anaesth; 2009 Jul; 56(7):489-96. PubMed ID: 19408066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Heparin monitoring during cardiopulmonary bypass in congenital heart surgery].
    Isomatsu Y; Imai Y; Seo K; Terada M; Aoki M; Shin'oka T
    Kyobu Geka; 2000 Nov; 53(12):1001-4. PubMed ID: 11079303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
    Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
    Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass surgery.
    Chomiak PN; Walenga JM; Koza MJ; Reilly TM; Turlapathy P; Pifarre R
    Circulation; 1993 Nov; 88(5 Pt 2):II407-12. PubMed ID: 7993389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A reevaluation of heparin requirements for cardiopulmonary bypass.
    Cardoso PF; Yamazaki F; Keshavjee S; Schaefers HJ; Hsieh CM; Wang LS; Glynn MF; Patterson GA; Cooper JD
    J Thorac Cardiovasc Surg; 1991 Jan; 101(1):153-60. PubMed ID: 1986159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.
    Gunaydin S; Farsak B; McCusker K; Vijay V; Sari T; Onur MA; Gurpinar A; Zorlutuna Y
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):135-42. PubMed ID: 19377380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heparin management during cardiac surgery with respect to various blood-conservation techniques.
    Boldt J; Zickmann B; Herold C; Scholz S; Dapper F; Hempelmann G
    Surgery; 1992 Mar; 111(3):260-5. PubMed ID: 1542853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of protamine dose on activated clotting time and thromboelastography in infants and small children undergoing cardiopulmonary bypass.
    Gautam NK; Schmitz ML; Harrison D; Zabala LM; Killebrew P; Belcher RH; Prodhan P; McKamie W; Norvell DC
    Paediatr Anaesth; 2013 Mar; 23(3):233-41. PubMed ID: 23279140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery.
    Babka R; Colby C; El-Etr A; Pifarré R
    J Thorac Cardiovasc Surg; 1977 May; 73(5):780-2. PubMed ID: 850438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rate of protamine administration: its effect on heparin reversal and antithrombin recovery after coronary artery surgery.
    Zaidan JR; Johnson S; Brynes R; Monroe S; Guffin AV
    Anesth Analg; 1986 Apr; 65(4):377-80. PubMed ID: 3954111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparison between arterial- and venous-sampled activated clotting time measurements.
    Zisman E; Rozenberg B; Katz Y; Ziser A
    Isr J Med Sci; 1997 Dec; 33(12):786-8. PubMed ID: 9464347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery?
    Teoh KH; Young E; Blackall MH; Roberts RS; Hirsh J
    J Thorac Cardiovasc Surg; 2004 Aug; 128(2):211-9. PubMed ID: 15282457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduction and elimination of systemic heparinization during cardiopulmonary bypass.
    von Segesser LK; Weiss BM; Garcia E; von Felten A; Turina MI
    J Thorac Cardiovasc Surg; 1992 Apr; 103(4):790-8; discussion 798-9. PubMed ID: 1548923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inactivated antithombin as anticoagulant reversal in a rat model of cardiopulmonary bypass: a potent and potentially safer alternative to protamine.
    Bianchini EP; Sebestyen A; Abache T; Bourti Y; Fontayne A; Richard V; Tamion F; Plantier JL; Doguet F; Borgel D
    Br J Haematol; 2018 Mar; 180(5):715-720. PubMed ID: 29363751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Administration of clemastine--H1 histamine receptor blocker in the prevention of haemodynamic disorders after protamine sulfate administration in patients subjected to coronary artery bypass grafting in extracorporeal circulation.
    Lango R; Mroziński P; Wujtewicz M; Suchorzewska J; Rogowski J; Narkiewicz M; Siebert J
    Med Sci Monit; 2000; 6(4):769-75. PubMed ID: 11208407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.